Bristol-Myers Squibb Company (BMY) — Business segments and KPIs
Revenue by business segment and geography for Bristol-Myers Squibb Company, with year-over-year trends.
FY 2025
| Segment | Revenue | % of total |
|---|---|---|
| Revenue by product | ||
| Eliquis | 14.44B | 30.0% |
| Opdivo | 10.05B | 20.9% |
| Orencia | 3.71B | 7.7% |
| Revlimid | 2.95B | 6.1% |
| Yervoy | 2.90B | 6.0% |
| Pomalyst/Imnovid | 2.73B | 5.7% |
| Reblozyl | 2.33B | 4.8% |
| Other Growth Brands | 1.92B | 4.0% |
| Breyanzi | 1.36B | 2.8% |
| Opdualag | 1.19B | 2.5% |
| Camzyos | 1.07B | 2.2% |
| Other Legacy Brands | 798M | 1.7% |
| Zeposia | 577M | 1.2% |
| Sprycel | 493M | 1.0% |
| Abecma | 427M | 0.9% |
| Abraxane | 368M | 0.8% |
| Sotyktu | 291M | 0.6% |
| Opdivo Ovantig | 238M | 0.5% |
| Krazati | 205M | 0.4% |
| Cobenfy | 155M | 0.3% |
| Revenue by region | ||
| UNITED STATES | 33.28B | 96.8% |
| Other Region | 1.09B | 3.2% |